Testing donor CAR-T cells for B-cell blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a B-cell blood cancer that is refractory or relapsed (came back after treatment).
- You need at least one measurable tumor (size 1.5 cm or larger) if you have lymphoma, or persistent minimal cancer cells if you have B-cell acute lymphoblastic leukemia.
- Your organs (liver, kidneys, heart, and bone marrow) must be functioning well enough based on blood tests and heart scan.
- You should be able to care for yourself (ECOG score 0–2) and have an expected survival of at least 12 weeks.
- You must not have had other treatments (chemotherapy, radiation, or certain drugs) within the last 2 weeks before starting.
- You cannot join if you have active infections, severe heart problems, certain other cancers, or a history of seizures or central nervous system disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This trial tests a new treatment called RN1201 for blood cancers like multiple myeloma, certain leukemias, and lymphomas that have not improved with standard treatments or have returned. The treatment targets specific markers on cancer cells (CD19 and BCMA) and may offer a new option for patients who have run out of standard choices.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
This trial tests a new type of immune cell therapy (CAR-T) that uses donor cells to target and kill leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has not responded to at least two prior treatments.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.